| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 43 | 2021 | 3271 | 3.280 |
Why?
|
| Informed Consent | 18 | 2019 | 280 | 2.350 |
Why?
|
| Clinical Trials, Phase I as Topic | 16 | 2018 | 150 | 2.230 |
Why?
|
| Decision Making | 15 | 2020 | 683 | 1.550 |
Why?
|
| Genes, BRCA2 | 5 | 2012 | 162 | 1.390 |
Why?
|
| Medical Oncology | 12 | 2015 | 413 | 1.380 |
Why?
|
| Genes, BRCA1 | 5 | 2012 | 191 | 1.380 |
Why?
|
| Truth Disclosure | 9 | 2012 | 75 | 1.260 |
Why?
|
| Attitude of Health Personnel | 11 | 2014 | 671 | 1.200 |
Why?
|
| Pharmaceutical Preparations | 2 | 2020 | 107 | 1.080 |
Why?
|
| Disclosure | 8 | 2018 | 97 | 1.040 |
Why?
|
| Clinical Trials as Topic | 8 | 2019 | 1118 | 0.930 |
Why?
|
| Comprehension | 8 | 2018 | 92 | 0.890 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2020 | 581 | 0.870 |
Why?
|
| Practice Patterns, Physicians' | 7 | 2014 | 649 | 0.850 |
Why?
|
| Patient Participation | 8 | 2016 | 244 | 0.820 |
Why?
|
| Research Subjects | 10 | 2014 | 78 | 0.800 |
Why?
|
| Patients | 4 | 2007 | 105 | 0.790 |
Why?
|
| Physicians | 4 | 2020 | 680 | 0.750 |
Why?
|
| Pharmacists | 2 | 2020 | 39 | 0.740 |
Why?
|
| Survivors | 6 | 2016 | 212 | 0.680 |
Why?
|
| Patient Preference | 2 | 2020 | 132 | 0.680 |
Why?
|
| Attitude to Health | 4 | 2007 | 217 | 0.670 |
Why?
|
| Ethics, Medical | 8 | 2008 | 291 | 0.660 |
Why?
|
| Genetic Testing | 3 | 2010 | 575 | 0.660 |
Why?
|
| Parent-Child Relations | 3 | 2012 | 87 | 0.650 |
Why?
|
| Prognosis | 15 | 2018 | 4041 | 0.620 |
Why?
|
| Caregivers | 2 | 2021 | 194 | 0.610 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2019 | 9 | 0.590 |
Why?
|
| Pharmacy | 1 | 2019 | 10 | 0.590 |
Why?
|
| Physician-Patient Relations | 6 | 2016 | 574 | 0.580 |
Why?
|
| Hospice Care | 3 | 2004 | 41 | 0.570 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 176 | 0.560 |
Why?
|
| Health Care Rationing | 1 | 2019 | 84 | 0.560 |
Why?
|
| Nontherapeutic Human Experimentation | 5 | 2000 | 19 | 0.560 |
Why?
|
| Hematologic Neoplasms | 5 | 2018 | 378 | 0.550 |
Why?
|
| Middle Aged | 44 | 2022 | 28794 | 0.530 |
Why?
|
| Research Personnel | 1 | 2018 | 81 | 0.520 |
Why?
|
| Humans | 75 | 2023 | 96382 | 0.520 |
Why?
|
| Surveys and Questionnaires | 16 | 2019 | 2951 | 0.510 |
Why?
|
| Complementary Therapies | 2 | 2008 | 58 | 0.500 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 2348 | 0.500 |
Why?
|
| Adult | 42 | 2022 | 28968 | 0.490 |
Why?
|
| Referral and Consultation | 4 | 2009 | 400 | 0.490 |
Why?
|
| Male | 43 | 2021 | 46116 | 0.460 |
Why?
|
| Female | 49 | 2022 | 50528 | 0.450 |
Why?
|
| Patient Selection | 5 | 2014 | 714 | 0.440 |
Why?
|
| Aged | 31 | 2022 | 21309 | 0.430 |
Why?
|
| Information Services | 2 | 2005 | 22 | 0.420 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 90 | 0.400 |
Why?
|
| Terminal Care | 2 | 2020 | 147 | 0.390 |
Why?
|
| Health Care Costs | 1 | 2015 | 252 | 0.380 |
Why?
|
| Stress, Psychological | 2 | 2016 | 378 | 0.370 |
Why?
|
| Internet | 2 | 2005 | 352 | 0.350 |
Why?
|
| Conflict of Interest | 3 | 2007 | 74 | 0.340 |
Why?
|
| Health Care Surveys | 5 | 2020 | 281 | 0.340 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 1981 | 0.330 |
Why?
|
| Parents | 2 | 2012 | 315 | 0.330 |
Why?
|
| Minors | 1 | 2010 | 15 | 0.320 |
Why?
|
| Aged, 80 and over | 14 | 2022 | 7277 | 0.310 |
Why?
|
| Young Adult | 11 | 2020 | 7318 | 0.300 |
Why?
|
| Oncologists | 2 | 2021 | 40 | 0.290 |
Why?
|
| Quality of Life | 9 | 2022 | 1869 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2018 | 2494 | 0.290 |
Why?
|
| Adult Children | 1 | 2009 | 13 | 0.290 |
Why?
|
| Mutation | 4 | 2023 | 4325 | 0.290 |
Why?
|
| Data Collection | 6 | 2008 | 375 | 0.290 |
Why?
|
| Adolescent | 13 | 2016 | 9948 | 0.280 |
Why?
|
| Motivation | 6 | 2021 | 334 | 0.270 |
Why?
|
| Palliative Care | 3 | 2020 | 280 | 0.270 |
Why?
|
| Therapeutic Human Experimentation | 2 | 1999 | 20 | 0.270 |
Why?
|
| Placebos | 2 | 2008 | 207 | 0.270 |
Why?
|
| Continuity of Patient Care | 1 | 2009 | 176 | 0.270 |
Why?
|
| Personal Autonomy | 5 | 2003 | 125 | 0.270 |
Why?
|
| United States | 10 | 2020 | 7976 | 0.260 |
Why?
|
| Adaptation, Psychological | 2 | 2009 | 189 | 0.250 |
Why?
|
| Heterozygote | 1 | 2008 | 386 | 0.250 |
Why?
|
| Interviews as Topic | 4 | 2016 | 374 | 0.250 |
Why?
|
| Pediatrics | 2 | 2012 | 398 | 0.240 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 408 | 0.230 |
Why?
|
| Anxiety | 2 | 2021 | 358 | 0.230 |
Why?
|
| Hospitals, Urban | 1 | 2005 | 64 | 0.220 |
Why?
|
| Volunteers | 1 | 2005 | 21 | 0.220 |
Why?
|
| Educational Status | 4 | 2016 | 203 | 0.220 |
Why?
|
| Empirical Research | 3 | 1999 | 20 | 0.210 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2009 | 162 | 0.210 |
Why?
|
| Spirituality | 1 | 2005 | 88 | 0.210 |
Why?
|
| Pilot Projects | 6 | 2016 | 962 | 0.200 |
Why?
|
| Illinois | 2 | 2020 | 517 | 0.200 |
Why?
|
| Biopsy | 1 | 2006 | 1196 | 0.190 |
Why?
|
| Awareness | 1 | 2003 | 90 | 0.190 |
Why?
|
| Mass Media | 1 | 2002 | 26 | 0.180 |
Why?
|
| Communication | 4 | 2017 | 450 | 0.170 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2023 | 837 | 0.170 |
Why?
|
| Research Design | 5 | 2014 | 645 | 0.160 |
Why?
|
| Biomedical Research | 2 | 2017 | 456 | 0.160 |
Why?
|
| Patient Education as Topic | 4 | 2017 | 406 | 0.160 |
Why?
|
| Breast Neoplasms | 4 | 2016 | 3221 | 0.160 |
Why?
|
| Cancer Survivors | 1 | 2022 | 105 | 0.160 |
Why?
|
| Risk Assessment | 6 | 2000 | 2528 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2012 | 2600 | 0.150 |
Why?
|
| Hospitals, University | 1 | 2020 | 192 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2010 | 971 | 0.150 |
Why?
|
| Eligibility Determination | 1 | 2019 | 40 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 631 | 0.150 |
Why?
|
| Patient Advocacy | 2 | 1997 | 65 | 0.150 |
Why?
|
| Child | 7 | 2014 | 7540 | 0.150 |
Why?
|
| Patient Care | 1 | 2020 | 100 | 0.150 |
Why?
|
| Drug Evaluation | 1 | 1999 | 109 | 0.140 |
Why?
|
| Research | 2 | 1999 | 256 | 0.140 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2020 | 111 | 0.140 |
Why?
|
| Knowledge | 2 | 2017 | 30 | 0.140 |
Why?
|
| Vinblastine | 1 | 1998 | 84 | 0.140 |
Why?
|
| Health Literacy | 2 | 2017 | 90 | 0.130 |
Why?
|
| Leukemia, Myeloid | 2 | 2012 | 241 | 0.130 |
Why?
|
| Remission Induction | 3 | 2016 | 741 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1998 | 271 | 0.120 |
Why?
|
| Paclitaxel | 1 | 1998 | 482 | 0.120 |
Why?
|
| Drug Therapy | 1 | 2016 | 67 | 0.120 |
Why?
|
| Family Health | 2 | 2009 | 156 | 0.120 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 558 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2021 | 4742 | 0.120 |
Why?
|
| Internal-External Control | 1 | 2016 | 47 | 0.120 |
Why?
|
| Marital Status | 1 | 2016 | 44 | 0.120 |
Why?
|
| Vulnerable Populations | 4 | 2014 | 95 | 0.120 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 810 | 0.110 |
Why?
|
| Transplantation Conditioning | 3 | 2007 | 387 | 0.110 |
Why?
|
| Religion | 1 | 2016 | 90 | 0.110 |
Why?
|
| Social Class | 1 | 2016 | 153 | 0.110 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 390 | 0.110 |
Why?
|
| Persons | 3 | 1999 | 6 | 0.100 |
Why?
|
| Karnofsky Performance Status | 3 | 2006 | 43 | 0.100 |
Why?
|
| Postal Service | 2 | 2012 | 24 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2008 | 3157 | 0.100 |
Why?
|
| Chicago | 2 | 2009 | 1488 | 0.100 |
Why?
|
| Adolescent Health Services | 1 | 2013 | 13 | 0.100 |
Why?
|
| Physicians, Family | 1 | 2013 | 36 | 0.090 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2007 | 379 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 3969 | 0.090 |
Why?
|
| Salvage Therapy | 2 | 2017 | 235 | 0.090 |
Why?
|
| Guideline Adherence | 2 | 2014 | 248 | 0.090 |
Why?
|
| Advance Directives | 1 | 2012 | 64 | 0.090 |
Why?
|
| Prevalence | 1 | 2016 | 1362 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 2 | 2012 | 244 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 303 | 0.090 |
Why?
|
| Treatment Outcome | 8 | 2010 | 9526 | 0.080 |
Why?
|
| Depression | 1 | 2016 | 592 | 0.080 |
Why?
|
| Melphalan | 3 | 2007 | 98 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2009 | 723 | 0.080 |
Why?
|
| Perception | 1 | 2012 | 187 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2020 | 1104 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1973 | 0.080 |
Why?
|
| Transplantation, Homologous | 5 | 2012 | 1024 | 0.080 |
Why?
|
| Myeloid Cells | 1 | 2010 | 119 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 3 | 2014 | 1090 | 0.080 |
Why?
|
| Stem Cell Transplantation | 2 | 2012 | 194 | 0.070 |
Why?
|
| Taiwan | 1 | 2008 | 25 | 0.070 |
Why?
|
| Federal Government | 2 | 1999 | 28 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 2 | 2001 | 284 | 0.070 |
Why?
|
| Government Regulation | 2 | 1999 | 49 | 0.070 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2023 | 134 | 0.070 |
Why?
|
| California | 1 | 2008 | 162 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2004 | 975 | 0.070 |
Why?
|
| China | 1 | 2008 | 268 | 0.070 |
Why?
|
| Consent Forms | 2 | 1999 | 11 | 0.070 |
Why?
|
| Health Behavior | 1 | 2009 | 198 | 0.060 |
Why?
|
| Herb-Drug Interactions | 1 | 2007 | 5 | 0.060 |
Why?
|
| Plant Preparations | 1 | 2007 | 20 | 0.060 |
Why?
|
| Ethics Committees, Research | 2 | 2014 | 34 | 0.060 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2022 | 324 | 0.060 |
Why?
|
| Time Factors | 4 | 2009 | 5524 | 0.060 |
Why?
|
| Medical Errors | 1 | 2007 | 93 | 0.060 |
Why?
|
| Medical Staff, Hospital | 1 | 2007 | 104 | 0.060 |
Why?
|
| Vitamins | 1 | 2007 | 93 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2019 | 391 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2012 | 838 | 0.060 |
Why?
|
| Logistic Models | 1 | 2009 | 1270 | 0.060 |
Why?
|
| Pedigree | 1 | 2008 | 971 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2006 | 112 | 0.060 |
Why?
|
| Dietary Supplements | 1 | 2007 | 147 | 0.060 |
Why?
|
| Age Factors | 2 | 2012 | 1957 | 0.060 |
Why?
|
| Quality Control | 1 | 2005 | 125 | 0.060 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2007 | 216 | 0.050 |
Why?
|
| Lymphokines | 1 | 1985 | 74 | 0.050 |
Why?
|
| Problem Solving | 1 | 2005 | 58 | 0.050 |
Why?
|
| Cladribine | 1 | 2004 | 30 | 0.050 |
Why?
|
| CD-ROM | 1 | 2004 | 3 | 0.050 |
Why?
|
| Teaching Materials | 1 | 2004 | 15 | 0.050 |
Why?
|
| Sex Factors | 2 | 2005 | 1135 | 0.050 |
Why?
|
| Third-Party Consent | 1 | 2004 | 24 | 0.050 |
Why?
|
| Drug Administration Schedule | 3 | 2004 | 836 | 0.050 |
Why?
|
| Risk Factors | 4 | 2006 | 6120 | 0.050 |
Why?
|
| Family Relations | 1 | 2004 | 38 | 0.050 |
Why?
|
| Life Expectancy | 1 | 2004 | 93 | 0.050 |
Why?
|
| Intention | 1 | 2004 | 53 | 0.050 |
Why?
|
| Deoxycytidine | 1 | 2004 | 216 | 0.050 |
Why?
|
| Metaphor | 1 | 2003 | 4 | 0.050 |
Why?
|
| Attitude to Death | 1 | 2003 | 31 | 0.050 |
Why?
|
| Refusal to Treat | 1 | 2003 | 27 | 0.050 |
Why?
|
| Terminally Ill | 1 | 2003 | 21 | 0.050 |
Why?
|
| Reimbursement Mechanisms | 1 | 2003 | 40 | 0.050 |
Why?
|
| Ethics, Clinical | 1 | 2003 | 47 | 0.050 |
Why?
|
| Bone Marrow | 1 | 1985 | 415 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2010 | 3905 | 0.050 |
Why?
|
| Culture | 1 | 2003 | 57 | 0.050 |
Why?
|
| Electronics | 1 | 2022 | 21 | 0.050 |
Why?
|
| Demography | 1 | 2003 | 192 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1985 | 324 | 0.050 |
Why?
|
| Students, Medical | 1 | 2007 | 446 | 0.040 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2002 | 56 | 0.040 |
Why?
|
| Focus Groups | 1 | 2003 | 208 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 312 | 0.040 |
Why?
|
| Mitoxantrone | 2 | 2012 | 65 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2005 | 515 | 0.040 |
Why?
|
| Human Experimentation | 1 | 2001 | 40 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2004 | 792 | 0.040 |
Why?
|
| Cytarabine | 2 | 2012 | 217 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2012 | 1738 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2007 | 1504 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2000 | 244 | 0.040 |
Why?
|
| Whole-Body Irradiation | 1 | 2000 | 70 | 0.040 |
Why?
|
| Drugs, Investigational | 1 | 2000 | 36 | 0.040 |
Why?
|
| Morals | 1 | 2021 | 103 | 0.040 |
Why?
|
| Etoposide | 1 | 2000 | 207 | 0.040 |
Why?
|
| Professional Staff Committees | 1 | 1999 | 6 | 0.040 |
Why?
|
| Researcher-Subject Relations | 1 | 1999 | 4 | 0.040 |
Why?
|
| HIV Wasting Syndrome | 1 | 1998 | 2 | 0.040 |
Why?
|
| Uncertainty | 1 | 1999 | 79 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 1999 | 165 | 0.040 |
Why?
|
| Mental Competency | 1 | 1999 | 49 | 0.040 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2018 | 6 | 0.030 |
Why?
|
| Forecasting | 1 | 1999 | 292 | 0.030 |
Why?
|
| History, 20th Century | 1 | 1999 | 318 | 0.030 |
Why?
|
| Control Groups | 1 | 1997 | 16 | 0.030 |
Why?
|
| Paternalism | 1 | 1997 | 24 | 0.030 |
Why?
|
| Germ Cells | 1 | 2018 | 133 | 0.030 |
Why?
|
| Recurrence | 3 | 2012 | 1235 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1937 | 0.030 |
Why?
|
| Neutropenia | 2 | 2010 | 211 | 0.030 |
Why?
|
| Acute Disease | 2 | 2012 | 850 | 0.030 |
Why?
|
| Testosterone | 1 | 1998 | 264 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1997 | 67 | 0.030 |
Why?
|
| Therapies, Investigational | 1 | 1996 | 18 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2001 | 435 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 1997 | 145 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2000 | 509 | 0.030 |
Why?
|
| Thrombocytopenia | 2 | 2010 | 194 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 1997 | 154 | 0.030 |
Why?
|
| Alemtuzumab | 2 | 2007 | 90 | 0.030 |
Why?
|
| Knee Prosthesis | 1 | 1996 | 24 | 0.030 |
Why?
|
| Lung | 2 | 2020 | 1389 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 2 | 2007 | 87 | 0.030 |
Why?
|
| Vidarabine | 2 | 2007 | 107 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 708 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2012 | 547 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2010 | 1525 | 0.030 |
Why?
|
| Income | 1 | 2016 | 96 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1997 | 262 | 0.030 |
Why?
|
| Disease-Free Survival | 3 | 2005 | 1184 | 0.030 |
Why?
|
| Graft vs Host Disease | 3 | 2005 | 377 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 905 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 243 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 902 | 0.030 |
Why?
|
| Cultural Diversity | 1 | 1995 | 64 | 0.030 |
Why?
|
| Trust | 1 | 1995 | 104 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 244 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 514 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2006 | 906 | 0.020 |
Why?
|
| Physician's Role | 1 | 1994 | 176 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 1079 | 0.020 |
Why?
|
| Canada | 1 | 2013 | 202 | 0.020 |
Why?
|
| Physicians, Primary Care | 1 | 2014 | 106 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1235 | 0.020 |
Why?
|
| Age of Onset | 1 | 2013 | 354 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2012 | 77 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 581 | 0.020 |
Why?
|
| Japan | 1 | 2012 | 301 | 0.020 |
Why?
|
| Diarrhea | 1 | 2012 | 180 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 351 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 659 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2014 | 331 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2007 | 1065 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 2 | 2007 | 1408 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 899 | 0.020 |
Why?
|
| Pamphlets | 1 | 2009 | 14 | 0.020 |
Why?
|
| Computer-Assisted Instruction | 1 | 2009 | 45 | 0.020 |
Why?
|
| Ethics, Research | 1 | 2009 | 53 | 0.020 |
Why?
|
| Social Perception | 1 | 2009 | 93 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2012 | 647 | 0.020 |
Why?
|
| Organizational Culture | 1 | 2007 | 33 | 0.020 |
Why?
|
| Safety Management | 1 | 2007 | 53 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2007 | 64 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2007 | 115 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 227 | 0.010 |
Why?
|
| Leukemia, Experimental | 1 | 1985 | 15 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1985 | 39 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 1985 | 39 | 0.010 |
Why?
|
| Karyotyping | 1 | 1985 | 220 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1985 | 122 | 0.010 |
Why?
|
| Retroviridae | 1 | 1985 | 73 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1985 | 140 | 0.010 |
Why?
|
| Lymphoma | 1 | 1986 | 249 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 1986 | 189 | 0.010 |
Why?
|
| Cell Line | 2 | 1986 | 2478 | 0.010 |
Why?
|
| Leukemia | 1 | 1986 | 303 | 0.010 |
Why?
|
| Fatigue | 1 | 2004 | 185 | 0.010 |
Why?
|
| Cell Survival | 1 | 1986 | 1012 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 2409 | 0.010 |
Why?
|
| Comorbidity | 1 | 2006 | 1027 | 0.010 |
Why?
|
| Survival Rate | 1 | 2006 | 2019 | 0.010 |
Why?
|
| Cytogenetic Analysis | 1 | 2001 | 70 | 0.010 |
Why?
|
| Mood Disorders | 1 | 2001 | 86 | 0.010 |
Why?
|
| Methotrexate | 1 | 2001 | 226 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2001 | 284 | 0.010 |
Why?
|
| Survival | 1 | 2000 | 22 | 0.010 |
Why?
|
| Stomatitis | 1 | 2000 | 30 | 0.010 |
Why?
|
| Cause of Death | 1 | 2001 | 277 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2000 | 71 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1985 | 2845 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2000 | 151 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 1998 | 66 | 0.010 |
Why?
|
| Menstruation | 1 | 1998 | 37 | 0.010 |
Why?
|
| Neutrophils | 1 | 2000 | 337 | 0.010 |
Why?
|
| Nutritional Status | 1 | 1998 | 81 | 0.010 |
Why?
|
| Body Composition | 1 | 1998 | 87 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2000 | 283 | 0.010 |
Why?
|
| Weight Gain | 1 | 1998 | 131 | 0.010 |
Why?
|
| Herpes Zoster | 1 | 1997 | 26 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2012 | 10719 | 0.010 |
Why?
|
| Role | 1 | 1996 | 9 | 0.010 |
Why?
|
| Graft Survival | 1 | 2000 | 988 | 0.010 |
Why?
|
| Osteoarthritis | 1 | 1996 | 82 | 0.010 |
Why?
|
| Knee Joint | 1 | 1996 | 174 | 0.010 |
Why?
|
| Liver | 1 | 2000 | 1222 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 1996 | 214 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 1996 | 178 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1996 | 580 | 0.010 |
Why?
|
| Mice | 2 | 1986 | 12495 | 0.010 |
Why?
|
| Pain | 1 | 1996 | 415 | 0.010 |
Why?
|
| Emotions | 1 | 1996 | 386 | 0.010 |
Why?
|
| Body Mass Index | 1 | 1996 | 837 | 0.010 |
Why?
|
| Heart Failure | 1 | 2000 | 1460 | 0.000 |
Why?
|
| Animals | 2 | 1986 | 28471 | 0.000 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1986 | 193 | 0.000 |
Why?
|
| Rats | 1 | 1986 | 4051 | 0.000 |
Why?
|